Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Delaying Anticancer Drug Delivery by Self-Assembly and Branching Effects of Minimalist Dendron-Drug Conjugates.

Correard F, Roy M, Terrasson V, Braguer D, Estève MA, Gingras M.

Chemistry. 2018 Jun 28. doi: 10.1002/chem.201801092. [Epub ahead of print]

PMID:
29952096
2.

Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression.

Le Grand M, Berges R, Pasquier E, Montero MP, Borge L, Carrier A, Vasseur S, Bourgarel V, Buric D, André N, Braguer D, Carré M.

Sci Rep. 2017 Mar 23;7:45136. doi: 10.1038/srep45136.

3.

The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells.

Bergès R, Tchoghandjian A, Honoré S, Estève MA, Figarella-Branger D, Bachmann F, Lane HA, Braguer D.

Mol Cancer Ther. 2016 Nov;15(11):2740-2749. Epub 2016 Aug 18.

4.

Ultrapure laser-synthesized Si-based nanomaterials for biomedical applications: in vivo assessment of safety and biodistribution.

Baati T, Al-Kattan A, Esteve MA, Njim L, Ryabchikov Y, Chaspoul F, Hammami M, Sentis M, Kabashin AV, Braguer D.

Sci Rep. 2016 May 6;6:25400. doi: 10.1038/srep25400.

5.

Negative regulation of EB1 turnover at microtubule plus ends by interaction with microtubule-associated protein ATIP3.

Velot L, Molina A, Rodrigues-Ferreira S, Nehlig A, Bouchet BP, Morel M, Leconte L, Serre L, Arnal I, Braguer D, Savina A, Honore S, Nahmias C.

Oncotarget. 2015 Dec 22;6(41):43557-70. doi: 10.18632/oncotarget.6196.

6.

An ultrasensitive LC-MS/MS method with liquid phase extraction to determine paclitaxel in both cell culture medium and lysate promising quantification of drug nanocarriers release in vitro.

Baati T, Schembri T, Villard C, Correard F, Braguer D, Estève MA.

J Pharm Biomed Anal. 2015 Nov 10;115:300-6. doi: 10.1016/j.jpba.2015.07.041. Epub 2015 Jul 29.

PMID:
26263058
7.

[Study impacto: Descriptive analyzis of pharmacist's clinical practice in onco-hematology].

Le Guen R, Madelaine I, Tournamille JF, Bellanger A, Astier A, Braguer D, Ollivier C, Bardin C, Lemare F, Daouphars M, Pinguet F, Latour JF, Vigneron J, Tilleul P.

Ann Pharm Fr. 2015 May;73(3):223-8. doi: 10.1016/j.pharma.2014.10.002. Epub 2014 Nov 12. French.

PMID:
25934530
8.

End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo.

Berges R, Baeza-Kallee N, Tabouret E, Chinot O, Petit M, Kruczynski A, Figarella-Branger D, Honore S, Braguer D.

Oncotarget. 2014 Dec 30;5(24):12769-87.

9.

Gold nanoparticles prepared by laser ablation in aqueous biocompatible solutions: assessment of safety and biological identity for nanomedicine applications.

Correard F, Maximova K, Estève MA, Villard C, Roy M, Al-Kattan A, Sentis M, Gingras M, Kabashin AV, Braguer D.

Int J Nanomedicine. 2014 Nov 21;9:5415-30. doi: 10.2147/IJN.S65817. eCollection 2014.

10.

ROS-mediated EB1 phosphorylation through Akt/GSK3β pathway: implication in cancer cell response to microtubule-targeting agents.

Le Grand M, Rovini A, Bourgarel-Rey V, Honore S, Bastonero S, Braguer D, Carre M.

Oncotarget. 2014 May 30;5(10):3408-23.

11.

A proapoptotic peptide conjugated to penetratin selectively inhibits tumor cell growth.

Alves ID, Carré M, Montero MP, Castano S, Lecomte S, Marquant R, Lecorché P, Burlina F, Schatz C, Sagan S, Chassaing G, Braguer D, Lavielle S.

Biochim Biophys Acta. 2014 Aug;1838(8):2087-98. doi: 10.1016/j.bbamem.2014.04.025. Epub 2014 May 2.

12.

Anti-migratory effect of vinflunine in endothelial and glioblastoma cells is associated with changes in EB1 C-terminal detyrosinated/tyrosinated status.

Rovini A, Gauthier G, Bergès R, Kruczynski A, Braguer D, Honoré S.

PLoS One. 2013 Jun 4;8(6):e65694. doi: 10.1371/journal.pone.0065694. Print 2013.

13.

ATIP3, a novel prognostic marker of breast cancer patient survival, limits cancer cell migration and slows metastatic progression by regulating microtubule dynamics.

Molina A, Velot L, Ghouinem L, Abdelkarim M, Bouchet BP, Luissint AC, Bouhlel I, Morel M, Sapharikas E, Di Tommaso A, Honoré S, Braguer D, Gruel N, Vincent-Salomon A, Delattre O, Sigal-Zafrani B, André F, Terris B, Akhmanova A, Di Benedetto M, Nahmias C, Rodrigues-Ferreira S.

Cancer Res. 2013 May 1;73(9):2905-15. doi: 10.1158/0008-5472.CAN-12-3565. Epub 2013 Feb 8.

14.

Bcl-2-enhanced efficacy of microtubule-targeting chemotherapy through Bim overexpression: implications for cancer treatment.

Savry A, Carre M, Berges R, Rovini A, Pobel I, Chacon C, Braguer D, Bourgarel-Rey V.

Neoplasia. 2013 Jan;15(1):49-60.

15.

Partial depletion of gamma-actin suppresses microtubule dynamics.

Po'uha ST, Honore S, Braguer D, Kavallaris M.

Cytoskeleton (Hoboken). 2013 Mar;70(3):148-60. doi: 10.1002/cm.21096. Epub 2013 Jan 17.

16.

Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells.

Pasquier E, Tuset MP, Street J, Sinnappan S, MacKenzie KL, Braguer D, Andre N, Kavallaris M.

Angiogenesis. 2013 Apr;16(2):373-86. doi: 10.1007/s10456-012-9321-x. Epub 2012 Nov 10.

17.

Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth.

Prudent R, Vassal-Stermann E, Nguyen CH, Pillet C, Martinez A, Prunier C, Barette C, Soleilhac E, Filhol O, Beghin A, Valdameri G, Honoré S, Aci-Sèche S, Grierson D, Antonipillai J, Li R, Di Pietro A, Dumontet C, Braguer D, Florent JC, Knapp S, Bernard O, Lafanechère L.

Cancer Res. 2012 Sep 1;72(17):4429-39. Epub 2012 Jul 3.

18.

Epothilone B inhibits migration of glioblastoma cells by inducing microtubule catastrophes and affecting EB1 accumulation at microtubule plus ends.

Pagano A, Honoré S, Mohan R, Berges R, Akhmanova A, Braguer D.

Biochem Pharmacol. 2012 Aug 15;84(4):432-43. doi: 10.1016/j.bcp.2012.05.010. Epub 2012 May 23.

PMID:
22634050
19.

Tyrosine-dependent capture of CAP-Gly domain-containing proteins in complex mixture by EB1 C-terminal peptidic probes.

Calligaris D, Manatschal C, Marcellin M, Villard C, Monsarrat B, Burlet-Schiltz O, Steinmetz MO, Braguer D, Lafitte D, Verdier-Pinard P.

J Proteomics. 2012 Jun 27;75(12):3605-16. doi: 10.1016/j.jprot.2012.04.006. Epub 2012 Apr 21.

PMID:
22543185
20.

Investigating microtubule dynamic instability using microtubule-targeting agents.

Honore S, Braguer D.

Methods Mol Biol. 2011;777:245-60. doi: 10.1007/978-1-61779-252-6_18.

PMID:
21773934
21.

Minimal analytical characterization of engineered nanomaterials needed for hazard assessment in biological matrices.

Bouwmeester H, Lynch I, Marvin HJ, Dawson KA, Berges M, Braguer D, Byrne HJ, Casey A, Chambers G, Clift MJ, Elia G, Fernandes TF, Fjellsbø LB, Hatto P, Juillerat L, Klein C, Kreyling WG, Nickel C, Riediker M, Stone V.

Nanotoxicology. 2011 Mar;5(1):1-11. doi: 10.3109/17435391003775266. Epub 2010 May 6.

PMID:
21417684
22.

Use of intravenous immunoglobulins in clinical practice: data from three French university hospitals.

Frauger E, Grassi J, Pradel V, Bornet C, Rouby F, Delorme J, Ousset S, Braguer D, Azulay JP, Penot-Ragon C, Harle JR, Bongrand MC, Weiller PJ, Pouget J, Michel G, Micallef J, Reynier JP, Tardieu S, Vanelle P, Blin O; Immunoglobulin Study Group.

Fundam Clin Pharmacol. 2011 Dec;25(6):753-61. doi: 10.1111/j.1472-8206.2010.00908.x. Epub 2011 Jan 11.

PMID:
21219439
23.

Microtubule-targeted agents: when mitochondria become essential to chemotherapy.

Rovini A, Savry A, Braguer D, Carré M.

Biochim Biophys Acta. 2011 Jun;1807(6):679-88. doi: 10.1016/j.bbabio.2011.01.001. Epub 2011 Jan 7. Review.

24.

MALDI in-source decay of high mass protein isoforms: application to alpha- and beta-tubulin variants.

Calligaris D, Villard C, Terras L, Braguer D, Verdier-Pinard P, Lafitte D.

Anal Chem. 2010 Jul 15;82(14):6176-84. doi: 10.1021/ac100996v.

PMID:
20552990
25.

Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells.

Rovini A, Carré M, Bordet T, Pruss RM, Braguer D.

Biochem Pharmacol. 2010 Sep 15;80(6):884-94. doi: 10.1016/j.bcp.2010.04.018. Epub 2010 Apr 22.

PMID:
20417191
26.

MVL-PLA2, a snake venom phospholipase A2, inhibits angiogenesis through an increase in microtubule dynamics and disorganization of focal adhesions.

Bazaa A, Pasquier E, Defilles C, Limam I, Kessentini-Zouari R, Kallech-Ziri O, El Battari A, Braguer D, El Ayeb M, Marrakchi N, Luis J.

PLoS One. 2010 Apr 12;5(4):e10124. doi: 10.1371/journal.pone.0010124.

27.

Microtubule targeting agents: from biophysics to proteomics.

Calligaris D, Verdier-Pinard P, Devred F, Villard C, Braguer D, Lafitte D.

Cell Mol Life Sci. 2010 Apr;67(7):1089-104. doi: 10.1007/s00018-009-0245-6. Epub 2010 Jan 28. Review.

PMID:
20107862
28.

Incompatibility of imipenem-cilastatin and amoxicillin.

Pourroy B, Bausset EM, Boulamery A, Villano LG, Braguer D.

Am J Health Syst Pharm. 2009 Jul 15;66(14):1253-4. doi: 10.2146/ajhp090023. No abstract available.

PMID:
19574595
29.

Transcriptional down-regulation of Bcl-2 by vinorelbine: identification of a novel binding site of p53 on Bcl-2 promoter.

Bourgarel-Rey V, Savry A, Hua G, Carré M, Bressin C, Chacon C, Imbert J, Braguer D, Barra Y.

Biochem Pharmacol. 2009 Nov 1;78(9):1148-56. doi: 10.1016/j.bcp.2009.06.025. Epub 2009 Jun 23.

PMID:
19555669
30.

Memo-RhoA-mDia1 signaling controls microtubules, the actin network, and adhesion site formation in migrating cells.

Zaoui K, Honoré S, Isnardon D, Braguer D, Badache A.

J Cell Biol. 2008 Nov 3;183(3):401-8. doi: 10.1083/jcb.200805107. Epub 2008 Oct 27.

31.

Tubulin proteomics: towards breaking the code.

Verdier-Pinard P, Pasquier E, Xiao H, Burd B, Villard C, Lafitte D, Miller LM, Angeletti RH, Horwitz SB, Braguer D.

Anal Biochem. 2009 Jan 15;384(2):197-206. doi: 10.1016/j.ab.2008.09.020. Epub 2008 Sep 18. Review. No abstract available.

32.

Antitumor activity of vinflunine: effector pathways and potential for synergies.

Braguer D, Barret JM, McDaid H, Kruczynski A.

Semin Oncol. 2008 Jun;35(3 Suppl 3):S13-21. doi: 10.1053/j.seminoncol.2008.01.011. Review.

PMID:
18538174
33.

Antiangiogenic vinflunine affects EB1 localization and microtubule targeting to adhesion sites.

Honoré S, Pagano A, Gauthier G, Bourgarel-Rey V, Verdier-Pinard P, Civiletti K, Kruczynski A, Braguer D.

Mol Cancer Ther. 2008 Jul;7(7):2080-9. doi: 10.1158/1535-7163.MCT-08-0156.

34.

Patupilone-induced apoptosis is mediated by mitochondrial reactive oxygen species through Bim relocalization to mitochondria.

Khawaja NR, Carré M, Kovacic H, Estève MA, Braguer D.

Mol Pharmacol. 2008 Oct;74(4):1072-83. doi: 10.1124/mol.108.048405. Epub 2008 Jul 1.

35.

Microtubules in apoptosis induction: are they necessary?

Estève MA, Carré M, Braguer D.

Curr Cancer Drug Targets. 2007 Dec;7(8):713-29. Review.

PMID:
18220532
36.

[Anasarca, a complication of chemotherapy with gemcitabine in two patients with pancreatic cancer].

Dahan L, Ressiot E, Cournede A, Ries P, Duluc M, Laquiere A, Laugier R, Braguer D, Seitz JF.

Gastroenterol Clin Biol. 2007 Dec;31(12):1143-5. French.

37.

Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP.

Makarov AA, Tsvetkov PO, Villard C, Esquieu D, Pourroy B, Fahy J, Braguer D, Peyrot V, Lafitte D.

Biochemistry. 2007 Dec 25;46(51):14899-906. Epub 2007 Dec 4.

PMID:
18052208
38.

Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment.

Pasquier E, André N, Braguer D.

Curr Cancer Drug Targets. 2007 Sep;7(6):566-81. Review.

PMID:
17896922
39.

Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.

Chinot OL, Barrié M, Fuentes S, Eudes N, Lancelot S, Metellus P, Muracciole X, Braguer D, Ouafik L, Martin PM, Dufour H, Figarella-Branger D.

J Clin Oncol. 2007 Apr 20;25(12):1470-5.

PMID:
17442989
40.

ADP ribosylation factor like 2 (Arl2) protein influences microtubule dynamics in breast cancer cells.

Beghin A, Honore S, Messana C, Matera EL, Aim J, Burlinchon S, Braguer D, Dumontet C.

Exp Cell Res. 2007 Feb 1;313(3):473-85. Epub 2006 Oct 28.

PMID:
17188265
41.

Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine.

Estève MA, Carré M, Bourgarel-Rey V, Kruczynski A, Raspaglio G, Ferlini C, Braguer D.

Mol Cancer Ther. 2006 Nov;5(11):2824-33.

42.

Efficacy of a combination of pemetrexed and multiple redo-surgery in an 11-year-old girl with a recurrent multifocal abdominal mesothelioma.

Milano E, Pourroy B, Rome A, Delarue A, Coze C, Gorincour G, Bouvier C, Braguer D, André N.

Anticancer Drugs. 2006 Nov;17(10):1231-4.

PMID:
17075325
43.

Microtubule-targeting agents in angiogenesis: where do we stand?

Pasquier E, Honoré S, Braguer D.

Drug Resist Updat. 2006 Feb-Apr;9(1-2):74-86. Epub 2006 May 22. Review.

PMID:
16714139
44.

Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells.

Pourroy B, Honoré S, Pasquier E, Bourgarel-Rey V, Kruczynski A, Briand C, Braguer D.

Cancer Res. 2006 Mar 15;66(6):3256-63.

45.

Decrease in c-Myc activity enhances cancer cell sensitivity to vinblastine.

Bressin C, Bourgarel-Rey V, Carré M, Pourroy B, Arango D, Braguer D, Barra Y.

Anticancer Drugs. 2006 Feb;17(2):181-7.

PMID:
16428936
46.

Understanding microtubule dynamics for improved cancer therapy.

Honore S, Pasquier E, Braguer D.

Cell Mol Life Sci. 2005 Dec;62(24):3039-56. Review.

PMID:
16314924
47.

Seventy-two-hour stability of Taxol in 5% dextrose or 0.9% sodium chloride in Viaflo, Freeflex, Ecoflac and Macoflex N non-PVC bags.

Pourroy B, Botta C, Solas C, Lacarelle B, Braguer D.

J Clin Pharm Ther. 2005 Oct;30(5):455-8.

PMID:
16164492
48.

[Oxaliplatin neurotoxicity: a report of three cases with post-operative exacerbation].

Cournede A, Ries P, Richard K, Guillain A, Dahan L, Grandval P, Pourroy B, Moutardier V, Hardwigsen J, Braguer D, Seitz JF.

Gastroenterol Clin Biol. 2005 Apr;29(4):461-4. French.

49.

Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.

Barrié M, Couprie C, Dufour H, Figarella-Branger D, Muracciole X, Hoang-Xuan K, Braguer D, Martin PM, Peragut JC, Grisoli F, Chinot O.

Ann Oncol. 2005 Jul;16(7):1177-84. Epub 2005 Apr 27.

PMID:
15857844
50.

Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells.

Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C, Braguer D.

Cancer Res. 2005 Mar 15;65(6):2433-40.

Supplemental Content

Loading ...
Support Center